Published in PLoS One on December 23, 2010
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Novel molecular and nanosensors for in vivo sensing. Theranostics (2013) 0.89
Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett (2013) 0.83
Flavin mononucleotide-based fluorescent proteins function in mammalian cells without oxygen requirement. PLoS One (2012) 0.82
Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imaging. PLoS One (2011) 0.80
HaloTag technology: a versatile platform for biomedical applications. Bioconjug Chem (2015) 0.80
A fluorescent protein scaffold for presenting structurally constrained peptides provides an effective screening system to identify high affinity target-binding peptides. PLoS One (2014) 0.78
Lipocalin2 as a plasma marker for tumors with hypoxic regions. Sci Rep (2014) 0.77
In vivo visualization of heterogeneous intratumoral distribution of hypoxia-inducible factor-1α activity by the fusion of high-resolution SPECT and morphological imaging tests. J Biomed Biotechnol (2012) 0.77
The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe. Sci Rep (2015) 0.77
In vivo imaging of brain ischemia using an oxygen-dependent degradative fusion protein probe. PLoS One (2012) 0.75
A novel injectable BRET-based in vivo imaging probe for detecting the activity of hypoxia-inducible factor regulated by the ubiquitin-proteasome system. Sci Rep (2016) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
In vivo protein transduction: delivery of a biologically active protein into the mouse. Science (1999) 10.70
Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol (2004) 9.05
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J (2003) 6.44
HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem Biol (2008) 6.00
Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J (2000) 4.85
Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer (2008) 4.50
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer (2008) 4.42
Proline hydroxylation and gene expression. Annu Rev Biochem (2005) 3.23
Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol (2008) 2.85
Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev (2004) 2.47
Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence (2002) 2.01
Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer (1995) 1.96
Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol (2005) 1.95
Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med (2005) 1.85
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77
Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life (2008) 1.51
Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res (2005) 1.41
Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx (2005) 1.36
Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging (2005) 1.35
In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol (2007) 1.29
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res (2002) 1.27
Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene (2007) 1.23
The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun (2007) 1.22
Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res (2009) 1.13
HIF-1alpha and p53: the ODD couple? Trends Biochem Sci (2005) 1.12
In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands. Bioconjug Chem (2009) 1.11
Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One (2009) 1.09
Nuclear translocation of hypoxia-inducible factors (HIFs): involvement of the classical importin alpha/beta pathway. Biochim Biophys Acta (2008) 1.05
Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A (2009) 1.04
Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol (1999) 0.98
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett (2006) 0.95
No-carrier-added synthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potential PET agent for detecting hypoxic but viable tissues. Int J Rad Appl Instrum A (1989) 0.78
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2005) 4.14
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Thyroid gland tumor diagnosis at US elastography. Radiology (2005) 3.26
Cervical lymph node metastases: diagnosis at sonoelastography--initial experience. Radiology (2007) 2.56
Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys (2005) 2.19
Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys (2008) 2.11
Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell (2006) 1.79
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77
Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem (2003) 1.57
Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J (2006) 1.52
Tumor hypoxia: a target for selective cancer therapy. Cancer Sci (2003) 1.49
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2002) 1.48
Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys (2009) 1.47
Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med (2011) 1.45
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.43
Effects of antioxidants and NO on TNF-alpha-induced adhesion molecule expression in human pulmonary microvascular endothelial cells. Respir Med (2004) 1.41
A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol (2010) 1.39
The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem (2008) 1.38
Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging (2005) 1.35
Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A (2010) 1.33
Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun (2012) 1.30
Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2. Proc Natl Acad Sci U S A (2003) 1.30
Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol Biol Phys (2006) 1.29
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.27
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res (2002) 1.27
The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun (2007) 1.22
Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology (2003) 1.20
Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology (2005) 1.17
Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol (2003) 1.14
Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res (2009) 1.13
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol (2010) 1.12
Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem (2004) 1.11
Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke (2010) 1.11
Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol (2007) 1.11
Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med (2006) 1.10
Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol (2002) 1.10
Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol (2006) 1.10
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (2011) 1.07
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci (2008) 1.04
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (2006) 1.04
The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev (2009) 1.03
Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. Radiology (2006) 1.03
Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma. Int J Clin Oncol (2004) 1.02
Induction of hypoxia-inducible factor 1 activity by muscarinic acetylcholine receptor signaling. J Biol Chem (2004) 1.01
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med (2004) 1.01
Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys (2005) 1.00
Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol (2002) 1.00
Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome. J Vasc Interv Radiol (2004) 1.00
IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res (2008) 0.99
Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials (2009) 0.98
Near-infrared fluorescent labeled peptosome for application to cancer imaging. Bioconjug Chem (2007) 0.98
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget (2010) 0.97
Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (2005) 0.96
Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004-2009. Breast Cancer (2012) 0.96
Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int (2002) 0.96
A consensus-based guideline defining clinical target volume for primary disease in external beam radiotherapy for intact uterine cervical cancer. Jpn J Clin Oncol (2011) 0.95
Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol (2012) 0.95
Bilateral breast-conserving therapy for bilateral breast cancer: results and consideration of radiation technique. Breast Cancer (2005) 0.95
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett (2006) 0.95
Persisting mild hypothermia suppresses hypoxia-inducible factor-1alpha protein synthesis and hypoxia-inducible factor-1-mediated gene expression. Am J Physiol Regul Integr Comp Physiol (2009) 0.95
Comparison of three radiotherapy treatment planning protocols of definitive external-beam radiation for localized prostate cancer. Int J Clin Oncol (2005) 0.95
CT-maximum intensity projection is a clinically useful modality for the detection of gastric varices. World J Gastroenterol (2005) 0.95
Phase II study of nimustine, carboplatin, vincristine, and interferon-beta with radiotherapy for glioblastoma multiforme: experience of the Kyoto Neuro-Oncology Group. J Neurosurg (2006) 0.94
Oxidative stress and altered antioxidant defenses in children with acute exacerbation of atopic dermatitis. Life Sci (2003) 0.94
Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Med Phys (2008) 0.94
Stereotactic radiosurgery for atypical and anaplastic meningiomas. J Neurooncol (2007) 0.94
Diffusion-tensor fiber tractography: intraindividual comparison of 3.0-T and 1.5-T MR imaging. Radiology (2006) 0.94
Dose-response relationship and dose optimization in radiotherapy of postoperative keloids. Radiother Oncol (2009) 0.93
Measurement of interfraction variations in position and size of target volumes in stereotactic body radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2009) 0.93
Dysregulation of IL-13 production by cord blood CD4+ T cells is associated with the subsequent development of atopic disease in infants. Pediatr Res (2002) 0.93
Insufficiency fractures after pelvic radiation therapy for uterine cervical cancer: an analysis of subjects in a prospective multi-institutional trial, and cooperative study of the Japan Radiation Oncology Group (JAROG) and Japanese Radiation Oncology Study Group (JROSG). Int J Radiat Oncol Biol Phys (2012) 0.92
Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer (2003) 0.92
Effects of magnesium sulphate administration on aquaporin 3 in rat gastrointestinal tract. Biol Pharm Bull (2011) 0.92
Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol (2015) 0.92
Development of severe complications caused by stent placement followed by definitive radiation therapy for T4 esophageal cancer. Int J Clin Oncol (2003) 0.91
Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors. Int J Mol Sci (2012) 0.91
A mechanism by which the osmotic laxative magnesium sulphate increases the intestinal aquaporin 3 expression in HT-29 cells. Life Sci (2010) 0.91
Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neurooncol (2012) 0.91
Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. Int J Radiat Oncol Biol Phys (2005) 0.91
Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. Radiology (2006) 0.91